Literature DB >> 20578553

Is Penicillium citrinum implicated in sago hemolytic disease?

Latifeh Atagazli1, Andrew R Greenhill, Wayne Melrose, Aisak G Pue, Jeffrey M Warner.   

Abstract

Sago hemolytic disease (SHD) is an acute hemolytic syndrome affecting rural Papua New Guineans who depend on the starch of Metroxylon sagu as a staple carbohydrate. It is a suspected mycotoxicosis associated with fungal succession in stored and perhaps poorly fermented sago. Despite a mortality rate of approximately 25%, little is know about the disease. Recent studies have identified Penicillium citrinum as a possible candidate in the etiology of SHD. This is based on the frequency of isolation from sago starch and the hemolytic nature of the organism as demonstrated when cultured on sheep and human blood agar. A highly non-polar lipophilic P. citrinum fraction from C18 solid phase extraction demonstrated high hemolytic activity in a semi-quantitative assay using both mouse and human erythrocytes. When the red cell membrane proteins were subjected to sodium dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) separation, cleavage of protein band 3 and spectrin was demonstrated. This breach of major structural red cell proteins is consistent with the severe hemolysis found in vivo. Our findings warrant further investigation into the hemolytic activity of P. citrinum and its role as the etiological agent of SHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20578553

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  1 in total

1.  Partial characteristics of hemolytic factors secreted from airborne Aspergillus and Penicillium, and an enhancement of hemolysis by Aspergillus micronesiensis CAMP-like factor via Staphylococcus aureus-sphingomyelinase.

Authors:  Sumonrat Kaveemongkonrat; Kwanjit Duangsonk; Jos Houbraken; Phimchat Suwannaphong; Nongnuch Vanittanakom; Malee Mekaprateep
Journal:  J Microbiol       Date:  2019-11-04       Impact factor: 3.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.